Actively Recruiting
Evaluation of LBL-024 Combined with Other Drugs for Advanced Solid Tumors Including NSCLC An Open-Label Phase II Study
Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2026-08-27
250
Participants Needed
24
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of LBL-024 combination therapy for patients with advanced non-small cell lung cancer NSCLC, a type of advanced solid tumor. This open-label, multicenter Phase II study aims to understand how well LBL-024 works when given alongside other cancer drugs. The study includes four groups of participants to assess different drug combinations and treatment approaches. Participants receive LBL-024 combined with drugs such as docetaxel, bevacizumab, pemetrexed, carboplatin, or paclitaxel through intravenous infusion. Each group starts with a 21-day safety observation period to monitor tolerability, followed by randomized assignment to specific treatment arms if safety is confirmed. Some groups continue with maintenance therapy using LBL-024 or other drugs after initial combination treatment. During the trial, participants undergo regular assessments including physical exams, laboratory tests, and imaging to monitor tumor response and safety. Researchers measure outcomes like objective response rate, disease control rate, and duration of response. Monitoring continues through a follow-up period after treatment ends to evaluate lasting effects and drug safety. The study plans to enroll up to 250 participants aged 18 to 75 years.
CONDITIONS
Brief Title
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Research Team
L
li Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here